We use third-party cookies in order to personalize your site experience. See our Privacy Policy.

Category thesis

high conviction 29 technologies

Biotechnology & Health

Biotechnology is entering a golden age where gene editing, mRNA, and AI-driven drug discovery are converging; the first approved CRISPR therapy proved the clinical thesis, and 250+ trials are underway.

The thesis

Category overview

CRISPR's first approved therapy (Casgevy, 2023) proved clinical viability. 250+ gene editing trials active. GLP-1 agonists are the biggest pharmaceutical story of the decade ($100B+ market). AI is accelerating drug discovery — Nvidia's $1B Eli Lilly partnership, Novo Nordisk + OpenAI. The convergence of gene editing, mRNA, and AI is creating a golden age of therapeutic innovation.

Technologies tracked

29 total

AI-driven drug discovery Biomanufacturing Bioprinting Brain-computer interfaces CAR-T cell therapy Cell and gene therapy manufacturing Cellular agriculture CRISPR gene editing Digital health and telemedicine Digital therapeutics Epigenetic editing Gene drives Gene sequencing GLP-1 receptor agonists Liquid biopsy Longevity science Microbiome therapeutics mRNA therapeutics Organoids Organs-on-chips Precision fermentation Protein engineering Psychedelic medicine Radiopharmaceuticals RNA therapeutics Spatial biology Synthetic biology Wearable health technology Xenotransplantation

The rest is inside

The full signal stack, KPIs and catalysts — live.

Every position is backed by talent flows, research and patent velocity, operational signals and a dated catalyst calendar. Log in to CanaryIQ to read the full analysis behind the verdict.